Ramgopal, M. et al: 5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials

Zurück zur Übersicht

23.-26.10.2022 / ID Week 2022

Studiensammlung zu HIV

Rieke, A. et al: Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in Treatment-Experienced (TE) People With HIV With a History of CKD

02.-05.11.2023 / ID Week

Sabranski, M. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort.

18.-21.10.2023 / EACS 2023

Esser, S. et al: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study.

18.-21.10.2023 / EACS 2023

Andreatta, K. et al: Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG) Based 3 Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence

11.-15.10.2023 / ID Week

Schellberg, S. et al: Three-Year B/F/TAF Use in Treatment-Naive and Treatment-Experienced People Living With HIV in the BICSTaR Cohort Study

23.-25.03.2023 / DÖAK

Stephan, C. et al: Longer-Term (3-Year) Effectiveness and Safety of B/F/TAF for the Treatment of HIV in the German BICSTaR Cohort

23.-25.03.2023 / DÖAK

Avihingsanon, A. et al: Predictors of Hepatitis B treatment response in people with HIV-1/HBV coinfection

19.-22.02.2023 / CROI

Ogbuagu, O. et al: Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH

19.-23.02.2023 / CROI

Orkin, C. et al: Outcomes After Switching From 144 Weeks of Blinded DTG/ABC/3TC or DTG+F/TAF to 96 Weeks of Open-label B/F/TAF

23.-26.10.2022 / HIV Drug Therapy 2022

Trottier, B. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study

23.-26.10.2022 / HIV Drug Therapy 2022